(2Z)-1-azabicyclo[2.2.2]oct-3-ylideneacetonitrile

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 奎宁环
• 英文名称: (2Z)-1-azabicyclo[2.2.2]oct-3-ylideneacetonitrile
• 英文别名: (2Z)-2-(1-azabicyclo[2.2.2]octan-3-ylidene)acetonitrile
• 化学式: C₉H₁₂N₂
• 分子量: 148.2
• InChiKey: CXNVAVCZGLHZBU-XLUWADSXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  27
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] NITROSATION PROCESS
  申请人：SMITHKLINE BEECHAM PLC

  公开号：WO1993017018A1

  公开（公告）日：1993-09-02

  (EN) A process for preparing compounds of formula (I), by nitrosating compounds of formula (II), compounds of formula (I) having pharmaceutical activity.(FR) Procédé de préparation de composés de la formule (I), consistant à faire subir une nitrosation aux composés de la formule (II). Les composés de la formule (I) présentent une activité pharmaceutique.

  一种制备化学式(I)化合物的过程，通过对化学式(II)化合物进行亚硝化反应，化学式(I)化合物具有药物活性。
• Nitrosation process
  申请人：——

  公开号：US20020143185A1

  公开（公告）日：2002-10-03

  1 A process for preparing compounds of formula (I), by nitrosating compounds of formula (II), compounds of formula (I) having pharmaceutical activity.

  一种制备式(I)化合物的方法，通过亚硝酰化式(II)化合物，式(I)化合物具有药物活性。
• NITROSATION PROCESS
  申请人：SMITHKLINE BEECHAM PLC

  公开号：EP0626961A1

  公开（公告）日：1994-12-07
• PROCESS FOR THE PREPARATION OF CYANO-METHOXYIMINOMETHYL DERIVATIVES
  申请人：SMITHKLINE BEECHAM PLC

  公开号：EP0626961B1

  公开（公告）日：2000-07-05
• Aminoisoxazoline Compounds as Agonists of Alpha7-Nicotinic Acetylcholine Receptors
  申请人：Forum Pharmaceuticals, Inc.

  公开号：US20170247393A1

  公开（公告）日：2017-08-31

  The present invention relates to novel aminoisoxazoline compounds, and pharmaceutical compositions of the same, that are suitable as agonists or partial agonists of α7-nAChR, and methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and/or improving cognitive function. In particular, methods of administering the compound or composition to a patient in need thereof, for example a patient with a cognitive deficiency and/or a desire to enhance cognitive function, that may derive a benefit therefrom.